Aurit: Raw material production line passes drug GMP compliance inspection.

Aurite announced that the company has received a "Notification of Compliance Inspection of Drug GMP" issued by the Zhejiang Provincial Drug Administration. From November 12th to 14th, 2025, inspections were conducted on workshops 806, 863, 802 and related production lines at its production address in Tiantai County, Zhejiang, involving the raw materials Mometasone furoate and Betamethasone. The conclusion was that they meet the relevant requirements. In 2024, the sales of Mometasone furoate and Betamethasone formulations in hospitals were 1.43 billion yuan and 0.15 billion yuan respectively. The results of this inspection will not have a significant impact on performance, as product sales are affected by multiple factors and uncertainties.